Pasithea Therapeutics announces activation of two South Korean trial sites

Pasithea Therapeutics (KTTA) announced activation of two South Korean clinical trial sites participating in its Phase 1/1b open label study to assess the safety, tolerability, pharmacokinetics, PK, and pharmacodynamics, PD, of PAS-004, in adult participants with neurofibromatosis type 1, NF1, with symptomatic and inoperable, incompletely resected, or recurrent plexiform neurofibromas. Dr. Tiago Reis Marques, chief executive officer of Pasithea commented, “With access to world-class facilities and an estimated 10,000 NF1 patients in South Korea, we believe our clinical sites in the country will play a pivotal role in the success of this trial. We are excited to include South Korean patients in our NF1 study and look forward to advancing meaningful treatment options for this community.”